学术报告
高分子科学系列讲座168讲：Dr.Klaus Pors, Towards Tumour-Selective Therapies by Re-engineering Natural Product Scaffolds
文章来源： 发布时间：2013-06-13
|
报告题目：Towards Tumour-Selective Therapies by Re-engineering Natural Product Scaffolds（No. PSLAB168-PS2013-06) |
|
报 告 人：Dr. Klaus Pors |
|
单 位：Institute of Cancer Therapeutics, University of Bradford, U.K. |
|
报告时间：2013年06月14日（星期五）上午10：30 |
|
报告地点：教育大厦6039 |
|
报告内容摘要：
Research in the Pors group is focussed on research at the interface between chemistry and biology. Traditional approaches to drug discovery such as target oriented synthesis and medicinal chemistry are used to develop focussed libraries of small molecules that are entirely new chemical entities or re-engineered versions of natural products. In addition, we use diversity-oriented synthesis to generate collections of small molecules of structural diverse architecture, which are used to probe new chemical space or known biological pathways that are not well understood. In the context of cancer, small molecules are designed to (i) exploit enzymatic and/or physiological conditions found unique to the tumour microenvironment or (ii) circumvent or exploit resistance mechanisms present in malignant tissue. As an extension of the latter, we are actively engaged in understanding how epigenetic therapy may affect the regulation and expression of drug metabolising enzymes (pharmacoepigenetics). In addition, we are also interested in developing molecular fluorescent probes that can be used to stain fixed or live cells with wide applications in routine and research laboratories utilising flow cytometry and fluorescence imaging methods. |
| 报告人介绍 |
Dr. Klaus Pors |
 |
Sept 2005 - present: Lecturer in Medicinal Chemistry & Team Leader, Institute of Cancer Therapeutics, University of Bradford, U.K.
|
